Company Directory - Novo Nordisk A/S
Company Details - Novo Nordisk A/S
Novo Nordisk A/S
WebsiteBagsværd, Denmark
ISIN: DK0062274199
Novo Nordisk A/S is a global healthcare company specializing in diabetes care and the development of innovative GLP-1 drugs for diabetes management and other chronic conditions.
CCI Score
CCI Score: Novo Nordisk A/S
18.81
-0.01%
Latest Event
Novo Nordisk Political Influence Profile
OpenSecrets data reveals significant lobbying spending and revolving door practices at Novo Nordisk. In the 2024 cycle, the company reported $686,783 in political contributions and $5,800,000 in lobbying expenditures. Additionally, a substantial number of its lobbyists have held previous government positions, raising concerns about corporate influence and potential facilitation of authoritarian policies.
Take Action
So what can you do? Support Novo Nordisk by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
SABOTEUR
Novo Nordisk A/S is currently rated as a Saboteur.
Latest Events
- FEB062025
OpenSecrets data reveals significant lobbying spending and revolving door practices at Novo Nordisk. In the 2024 cycle, the company reported $686,783 in political contributions and $5,800,000 in lobbying expenditures. Additionally, a substantial number of its lobbyists have held previous government positions, raising concerns about corporate influence and potential facilitation of authoritarian policies.
-40
Political Contributions and Lobbying Efforts
March 25
Novo Nordisk's reported lobbying expenditure of $5.8M in 2024, combined with $686K in political contributions, suggests a strategic effort to shape policy environments. This level of political spending may contribute to undemocratic practices by influencing policy in favor of corporate interests and, indirectly, authoritarian agendas.
-30
Executive Political Engagement
March 25
The data shows that a notable fraction of Novo Nordisk's lobbyists have previously held government roles (54 out of 77 in 2023 and 47 out of 66 in 2024). This revolving door phenomenon raises serious concerns regarding potential conflicts of interest and undue executive influence over public policy in ways that may bolster authoritarian practices.
- JAN012025
Novo Nordisk has updated its Labour Code of Conduct effective January 2025, demonstrating a robust commitment to labor rights, fair working conditions, human rights, and non-discrimination in the workplace.
+90
Labor Relations and Human Rights Practices
March 25
The published Labour Code of Conduct details comprehensive measures to ensure compliance with international human rights standards at work. Novo Nordisk's commitment—including fair work hours, equitable wages, robust grievance mechanisms, non-discrimination, and freedom of association—reflects a strong positive stance on labor relations and human rights practices, countering exploitative labor practices that could otherwise fuel authoritarian economic dominance.
- NOV012024
Novo Nordisk released a comprehensive 2024 Responsible Sourcing Standard outlining rigorous supplier guidelines to ensure adherence to international human rights, environmental protection, and anti-corruption measures.
+70
Supply Chain Ethics
March 25
Novo Nordisk's Responsible Sourcing Standard mandates that all suppliers adhere to strict ethical guidelines including human rights and environmental protection. This move minimizes the risk of complicity in human rights abuses in its supply chain and positions the company as proactively responsible.
Novo Nordisk A/S : Procurement in Novo Nordisk (2024 responsible sourcing standards)
+65
Labor Relations and Human Rights Practices
March 25
The standard emphasizes protection of human, employment, and social rights, aligning with internationally recognized labor and human rights principles. This commitment helps ensure that suppliers maintain fair labor practices, reducing any risk of exploitation.
Novo Nordisk A/S : Procurement in Novo Nordisk (2024 responsible sourcing standards)
- JUN142024
Novo Nordisk published its 2023 Human Rights Due Diligence Report detailing comprehensive measures across its operations and supply chain to uphold human rights in line with the Transparency Act in Norway.
+80
Labor Relations and Human Rights Practices
March 31
The report demonstrates robust human rights due diligence through extensive employee training, clear corporate human rights requirements, a dedicated compliance hotline, and integrated risk management practices, underscoring strong labor relations and human rights practices.
+70
Supply Chain Ethics
March 31
The report details significant initiatives in responsible sourcing, third-party due diligence, and supplier audits, strengthening the company’s supply chain ethics and ensuring adherence to international human rights standards.
- MAY172024
Novo Nordisk published its seventh Modern Slavery Statement for the financial year ending December 31, 2023, detailing comprehensive measures to prevent modern slavery and forced labour in its global supply chain, along with robust labour rights practices and responsible sourcing initiatives.
+80
Labor Relations and Human Rights Practices
March 31
The statement outlines extensive labour practices and human rights protocols, including a strengthened Labour Code of Conduct, mandatory human rights training for employees, and measures to prevent labour abuse. These efforts demonstrate a strong commitment to safeguarding worker rights and preventing forced or bonded labour, reflecting a positive anti-fascist and pro-worker stance.
+75
Supply Chain Ethics
March 31
The document provides an in-depth overview of Novo Nordisk's Responsible Sourcing Programme, including risk assessments, audits, corrective action plans, and collaborative efforts with industry bodies to mitigate modern slavery risks within its extensive supply chain. This proactive approach to supply chain ethics aligns with anti-authoritarian and human rights standards.
- MAY172024
Novo Nordisk's 2023 Modern Slavery Statement details robust measures in ethical labor practices and supply chain management, demonstrating a strong commitment to human rights and responsible sourcing in its global operations.
+85
Labor Relations and Human Rights Practices
March 25
The statement outlines comprehensive labor and human rights practices, including strict labor standards, adherence to living wage policies, and mandatory human rights training programs. These measures contribute positively by protecting workers' rights and preventing labor abuses.
+80
Supply Chain Ethics
March 25
The document provides extensive details on the Responsible Sourcing Programme, including risk assessments, supplier audits, and corrective action plans. This proactive approach to managing and mitigating modern slavery risks in the supply chain strongly supports ethical business practices.
- DEC312023
Novo Nordisk spent approximately $5,239,615 on lobbying efforts during 2023, as reported by OpenSecrets. This expenditure highlights the company’s active involvement in shaping public policy through corporate political actions.
-40
Political Contributions and Lobbying Efforts
March 31
Novo Nordisk's reported $5.24 million lobbying expenditure in 2023 indicates significant efforts to influence political outcomes. From an anti-fascist perspective, such extensive lobbying can undermine democratic accountability by prioritizing corporate interests over those of marginalized communities and the public good, especially when transparency around policy objectives is lacking.
- JUN302023
Novo Nordisk spent nearly $2.9 million on federal lobbying in the first half of 2023 and hired three new lobbying firms, including personnel with revolving door ties, to push for the removal of Medicare restrictions on obesity treatments. This move is seen as an effort to shape healthcare policy despite concerns over excessive corporate political influence.
-40
Political Contributions and Lobbying Efforts
March 31
The company's significant lobbying expenditure and the hiring of new lobbying firms—with personnel having revolving door experience—highlight a deepening reliance on corporate political influence. While the goal of expanding Medicare coverage for obesity drugs could benefit public health, the method raises concerns about the undemocratic influence of corporate money on policymaking, aligning with patterns of behavior that undermine transparent and equitable political processes.
Novo Nordisk boosts lobbying as it seeks Medicare coverage for obesity drugs
- JUL072022
Unionized workers at Novo Nordisk Korea staged a protest rally over unilateral changes in wage negotiations and incentive reductions, highlighting concerns about deteriorating labor relations and fair treatment.
-60
Labor Relations and Human Rights Practices
March 25
Novo Nordisk Korea's management unilaterally altered agreed wage increase rates and reduced performance incentives without proper union consultation, undermining established labor agreements. This act has damaged trust between management and workers, reflecting poor labor relations and contributing to authoritarian corporate practices that disregard fair worker rights.
Novo Nordisk union holds protest rally over wages and incentives
- APR302018
Since 2015, Novo Nordisk has doubled its political donations and ramped up its lobbying spending in response to scrutiny over soaring insulin prices. This aggressive move raises concerns about the company’s strategy to influence policy debates on drug pricing, potentially undermining democratic processes and prioritizing corporate profit over patient needs.
-70
Political Contributions and Lobbying Efforts
March 25
Novo Nordisk significantly increased its political contributions and lobbying efforts with $405,000 in campaign donations and $3.2 million in lobbying expenditures in 2017. This deliberate escalation of political spending is intended to shape legislative debates on drug pricing, reflecting a willingness to exploit political influence to safeguard corporate profits at the expense of public health.
How A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
-50
Business Practices and Ethical Responsibility
March 25
In addition to its aggressive political activities, Novo Nordisk faces criticism for its business practices, notably the steep increases in insulin prices that have burdened patients. The company's strategy to counter regulatory and public pressure by prioritizing profit margins over affordable healthcare raises ethical concerns.
How A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
Alternatives
North Chicago, United States
-31.53
Indianapolis, United States
-35.34
Corporation
-12.69
Tokyo, Japan
-7.42
Hyderabad, India
-53.10
Corporation
-13.53
Barcelona, Spain
57.57
Japan
26.16
Thousand Oaks, USA
13.63
Kenilworth, United States
12.75
Corporate Financials
- Revenue
- 2022
- $19.54B
- Total Assets
- 2022
- $47.60B
- Operating Income
- 2022
- $19.08B
- Total Equity
- 2022
- $39.10B
Employees: 48,000
Industries
- 325411
- Medicinal and Botanical Manufacturing
- 325412
- Pharmaceutical Preparation Manufacturing
- 424210
- Drugs and Druggists' Sundries Merchant Wholesalers
- 541714
- Research and Development in Biotechnology (except Nanobiotechnology)